Example of Current Cancer Therapy Reviews format
Recent searches

Example of Current Cancer Therapy Reviews format Example of Current Cancer Therapy Reviews format Example of Current Cancer Therapy Reviews format Example of Current Cancer Therapy Reviews format Example of Current Cancer Therapy Reviews format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Current Cancer Therapy Reviews format Example of Current Cancer Therapy Reviews format Example of Current Cancer Therapy Reviews format Example of Current Cancer Therapy Reviews format Example of Current Cancer Therapy Reviews format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Current Cancer Therapy Reviews — Template for authors

Publisher: Bentham Science
Categories Rank Trend in last 3 yrs
Oncology #280 of 340 down down by 10 ranks
Cancer Research #185 of 207 down down by 7 ranks
Molecular Medicine #159 of 167 down down by 4 ranks
journal-quality-icon Journal quality:
Low
calendar-icon Last 4 years overview: 72 Published Papers | 39 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 09/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Springer

Quality:  
High
CiteRatio: 10.4
SJR: 5.06
SNIP: 2.281
open access Open Access
recommended Recommended

Springer

Quality:  
High
CiteRatio: 34.3
SJR: 7.274
SNIP: 4.213
open access Open Access
recommended Recommended

Nature

Quality:  
High
CiteRatio: 16.0
SJR: 4.539
SNIP: 2.28
open access Open Access
recommended Recommended

American Association for Cancer Research

Quality:  
High
CiteRatio: 15.8
SJR: 4.103
SNIP: 1.983

Journal Performance & Insights

CiteRatio

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

A measure of average citations received per peer-reviewed paper published in the journal.

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

0.5

CiteRatio for Current Cancer Therapy Reviews from 2016 - 2020
Year Value
2020 0.5
2019 0.5
2018 0.5
2017 0.6
2016 0.5
graph view Graph view
table view Table view

0.128

SJR for Current Cancer Therapy Reviews from 2016 - 2020
Year Value
2020 0.128
2019 0.128
2018 0.14
2017 0.14
2016 0.183
graph view Graph view
table view Table view

0.157

157% from 2019

SNIP for Current Cancer Therapy Reviews from 2016 - 2020
Year Value
2020 0.157
2019 0.061
2018 0.105
2017 0.105
2016 0.11
graph view Graph view
table view Table view

insights Insights

  • This journal’s CiteRatio is in the top 10 percentile category.

insights Insights

  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 157% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Current Cancer Therapy Reviews

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Bentham Science

Current Cancer Therapy Reviews

Approved by publishing and review experts on SciSpace, this template is built as per for Current Cancer Therapy Reviews formatting guidelines as mentioned in Bentham Science author instructions. The current version was created on 08 Jun 2020 and has been used by 796 authors to write and format their manuscripts to this journal.

Medicine

i
Last updated on
08 Jun 2020
i
ISSN
1573-3947
i
Impact Factor
Low - 0.178
i
Open Access
No
i
Sherpa RoMEO Archiving Policy
Yellow faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
Vancouver
i
Citation Type
Numbered
[25]
i
Bibliography Example
Blonder, G E, Tinkham, M, & Klapwijk, T M. Transition from metallic to tunnel- ing regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B. 2013;87(10):100510.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.2174/157339406777934717
Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy.
Yong Wang1, Virginia Probin, Daohong Zhou

Abstract:

Bone marrow (BM) suppression is the important dose-limiting side effect of chemotherapy and radiotherapy for cancer. Although acute myelosuppression is an immediate concern for patients undergoing cancer therapy, its management has been improved significantly in recent years by the use of various hematopoietic growth factors.... Bone marrow (BM) suppression is the important dose-limiting side effect of chemotherapy and radiotherapy for cancer. Although acute myelosuppression is an immediate concern for patients undergoing cancer therapy, its management has been improved significantly in recent years by the use of various hematopoietic growth factors. However, many patients receiving chemotherapy and/or ionizing radiation (IR) also develop residual (or long-term) BM injury (a sustained decrease in HSC reserves due to an impairment in HSC self-renewal) after the recovery from acute myelosuppression. Unlike acute myelosuppression, residual BM injury is latent and long lasting and shows little tendency for recovery. Following additional hematopoietic stress such as subsequent cycles of consolidation cancer treatment or autologous BM transplantation, residual BM injury can deteriorate to become a hypoplastic or myelodysplastic syndrome. This article review some of the new developments in elucidating the cellular and molecular mechanisms whereby chemotherapy and radiotherapy cause residual BM injury. Particularly, we discuss the role of induction of hematopoietic stem cell (HSC) senescence via the p53-p21(Cip1/Waf1) and/or p16(Ink4a)-RB pathways in the induction of the injury and the therapeutic potential of molecularly targeting these pathways for amelioration of chemotherapy- and radiotherapy-induced long-term BM toxicity. read more read less

Topics:

Bone marrow (53%)53% related to the paper, Radiation therapy (52%)52% related to the paper, Transplantation (51%)51% related to the paper, Cancer (51%)51% related to the paper, Chemotherapy (51%)51% related to the paper
View PDF
145 Citations
open accessOpen access Journal Article DOI: 10.2174/157339411797642597
Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment.
Ticiana Leal1, Julie E Chang, Minesh P. Mehta, H. Ian Robins

Abstract:

As therapeutic options and supportive care for the treatment of neoplastic disease have improved, there has been an associated increase in the incidence of leptomeningeal disease. In this review, the clinical presentation, natural history, diagnostic evaluation, and treatment options for this often devastating sequela of soli... As therapeutic options and supportive care for the treatment of neoplastic disease have improved, there has been an associated increase in the incidence of leptomeningeal disease. In this review, the clinical presentation, natural history, diagnostic evaluation, and treatment options for this often devastating sequela of solid tumors, lymphoma, and leukemia will be summarized. The therapeutic efficacy of ionizing radiation, systemic agents, and intrathecal drugs will be examined from the existing literature. Additionally the pathophysiology, which in part defines the therapeutic limitations in approaching this patient population, will be discussed in order to assist in individualized clinical decision making. read more read less
View PDF
105 Citations
open accessOpen access Journal Article DOI: 10.2174/1573394711309010006
The Current and Future Therapies for Human Osteosarcoma

Abstract:

Osteosarcoma (OS) is the most common non-hematologic malignant tumor of bone in adults and children. As sarcomas are more common in adolescents and young adults than most other forms of cancer, there are a significant number of years of life lost secondary to these malignancies. OS is associated with a poor prognosis secondar... Osteosarcoma (OS) is the most common non-hematologic malignant tumor of bone in adults and children. As sarcomas are more common in adolescents and young adults than most other forms of cancer, there are a significant number of years of life lost secondary to these malignancies. OS is associated with a poor prognosis secondary to a high grade at presentation, resistance to chemotherapy and a propensity to metastasize to the lungs. Current OS management involves both chemotherapy and surgery. The incorporation of cytotoxic chemotherapy into therapeutic regimens escalated cure rates from <20% to current levels of 65-75%. Furthermore, limb-salvage surgery is now offered to the majority of OS patients. Despite advances in chemotherapy and surgical techniques over the past three decades, there has been stagnation in patient survival outcome improvement, especially in patients with metastatic OS. Thus, there is a critical need to identify novel and directed therapy for OS. Several Phase I trials for sarcoma therapies currently ongoing or recently completed have shown objective responses in OS. Novel drug delivery mechanisms are currently under phase II and III clinical trials. Furthermore, there is an abundance of preclinical research which holds great promise in the development of future OS-directed therapeutics. Our continuously improving knowledge of the molecular and cell-signaling pathways involved in OS will translate into more effective therapies for OS and ultimately improved patient survival. The present review will provide an overview of current therapies, ongoing clinical trials and therapeutic targets under investigation for OS. read more read less

Topics:

Sarcoma (50%)50% related to the paper
View PDF
62 Citations
Journal Article DOI: 10.2174/1573394052952456
Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment

Abstract:

The selective targeting of established tumor vasculature represents an attractive new anticancer drug strategy, distinct from inhibiting angiogenesis. This is based on the concept that, in contrast to targeting individual tumor cells, the killing of relatively few vascular endothelial cells could result in the death of a larg... The selective targeting of established tumor vasculature represents an attractive new anticancer drug strategy, distinct from inhibiting angiogenesis. This is based on the concept that, in contrast to targeting individual tumor cells, the killing of relatively few vascular endothelial cells could result in the death of a large area of tumor (from lack of oxygen and nutrients), drug delivery to vasculature is less challenging than to large solid tumors (which may harbor regions of hypoxia) and, moreover, cells that comprise vasculature (such as endothelial cells) are more genetically stable than tumor cells and hence less likely to acquire changes causing drug resistance. There is accumulating evidence that there are inherent differences in the vasculature of tumors, both morphologic and biochemical, in comparison to normal organs, thus providing a rational basis for this approach. Vascular disrupting agents (VDAs) are now being tested clinically; several are also in late preclinical development. A major class of small molecule VDA is those targeting tubulin, e.g., combretastatin A4 phosphate (CA4P), ZD6126 and AVE8062A. Another distinct non-tubulin based compound, the flavonoid 5,6-dimethyl xanthenone 4-acetic acid (DMXAA, AS1404) induces direct apoptosis of endothelial cells and secondary induction of various vasoactive agents (such as serotonin and tumor necrosis factor α). These agents have all completed Phase I clinical evaluation; dose-limiting toxicities are generally non-overlapping with conventional cytotoxics; there has been evidence of efficacy. A common theme, now being pursued clinically, is that VDAs are expected to show maximum therapeutic benefit when used, intermittently rather than chronically and in combination with either conventional cytotoxics (such as platins or taxanes) or radiotherapy. Thereby, complementary kill of the central compartment of tumors (by VDAs) and the proliferating, well oxygenated, periphery (by cytotoxics or radiotherapy) , is predicted. Non-invasive imaging techniques such as dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) have proven useful in the clinical monitoring of VDAs. A variety of additional small molecule anti-tubulin agents, N-cadherin inhibitors and antibody-based products (e.g., delivering effectors such as tissue factor to tumor blood vessels) are in earlier stages of development. The vascular targeting field is entering a particularly exciting phase; the next 1-2 years will be crucial in establishing clinical proof of principle for this approach. read more read less

Topics:

Angiogenesis (53%)53% related to the paper, ZD6126 (51%)51% related to the paper
View PDF
53 Citations
Journal Article DOI: 10.2174/157339410791202583
HPV and Therapeutic Vaccines: Where are We in 2010?
Barbara Ma1, Yijie Xu1, Chien Fu Hung, Tzyy Choou Wu

Abstract:

The discovery of human papillomavirus (HPV) as a necessary etiological factor for cervical cancer has spurred the development of preventive and therapeutic HPV vaccines for the control of HPV-associated malignancies including cervical, vulvar, vaginal, and a subset of head and neck cancers. The commercial preventive HPV vacci... The discovery of human papillomavirus (HPV) as a necessary etiological factor for cervical cancer has spurred the development of preventive and therapeutic HPV vaccines for the control of HPV-associated malignancies including cervical, vulvar, vaginal, and a subset of head and neck cancers. The commercial preventive HPV vaccines, Gardasil and Cervarix, use HPV virus-like particles to generate neutralizing antibodies against HPV major capsid protein L1. However, they do not exert therapeutic effects on existing lesions and are unlikely to have an immediate impact on the prevalence of cervical cancer due to their cost and limited availability in developing countries, which account for more than 80% of cer- vical cancers. Thus, there is an urgent need for therapeutic HPV vaccines. Therapeutic HPV vaccines can eliminate pre- existing lesions and infections by generating cellular immunity against HPV-infected cells. HPV E6 and E7 oncoproteins represent ideal targets for therapeutic intervention because of their constitutive expression in HPV-associated tumors and their crucial role in the induction and maintenance of HPV-associated disease. This review discusses the current progress of various therapeutic HPV vaccine approaches, including live vector-based, peptide/protein-based, nucleic acid-based and cell-based vaccines targeting E6 and/or E7 antigens, and their future prospects for the control of HPV-associated ma- lignancies. read more read less

Topics:

HPV vaccines (65%)65% related to the paper, Gardasil (65%)65% related to the paper, HPV Major Capsid Protein L1 (62%)62% related to the paper, Cervical cancer (54%)54% related to the paper, Cervarix (53%)53% related to the paper
42 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Current Cancer Therapy Reviews.

It automatically formats your research paper to Bentham Science formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Current Cancer Therapy Reviews format uses Vancouver citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Current Cancer Therapy Reviews in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Current Cancer Therapy Reviews guidelines and auto format it.

2. Do you follow the Current Cancer Therapy Reviews guidelines?

Yes, the template is compliant with the Current Cancer Therapy Reviews guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Current Cancer Therapy Reviews?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Current Cancer Therapy Reviews citation style.

4. Can I use the Current Cancer Therapy Reviews templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Current Cancer Therapy Reviews.

5. Can I use a manuscript in Current Cancer Therapy Reviews that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Current Cancer Therapy Reviews that you can download at the end.

6. How long does it usually take you to format my papers in Current Cancer Therapy Reviews?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Current Cancer Therapy Reviews.

7. Where can I find the template for the Current Cancer Therapy Reviews?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Current Cancer Therapy Reviews's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Current Cancer Therapy Reviews's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Current Cancer Therapy Reviews an online tool or is there a desktop version?

SciSpace's Current Cancer Therapy Reviews is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Current Cancer Therapy Reviews?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Current Cancer Therapy Reviews?”

11. What is the output that I would get after using Current Cancer Therapy Reviews?

After writing your paper autoformatting in Current Cancer Therapy Reviews, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Current Cancer Therapy Reviews's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Current Cancer Therapy Reviews?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Current Cancer Therapy Reviews. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Current Cancer Therapy Reviews?

The 5 most common citation types in order of usage for Current Cancer Therapy Reviews are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Current Cancer Therapy Reviews?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Current Cancer Therapy Reviews's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Current Cancer Therapy Reviews in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Current Cancer Therapy Reviews Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Current Cancer Therapy Reviews formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template